KeithEStockerl-GoldsteinMD

Oncology • Saint Louis, MO

Hematologic Oncology

Professor of Medicine BMT/Leukemia Program

Join to view full profile

Dr. Stockerl-Goldstein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Stockerl-Goldstein's full profile

Already have an account?

Office
4921 Parkview Pl
7th Floor
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-7551
Is this information wrong?

Summary

Dr. Keith Stockerl-Goldstein is an oncologist in Saint Louis, MO and is affiliated with multiple hospitals in the area, including Barnes-Jewish Hospital and Siteman Cancer Center. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 26 years. He specializes in hematologic oncology and is experienced in hematologic oncology, hematopoietic stem cell transplantation, multiple myeloma, amyloidosis, leukemia, and transplantation conditioning.
He currently serves as an Associate Program Director for the Hematology /Oncology Fellowship Program.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1993 - 1996
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1991 - 1993
David Geffen School of Medicine at UCLAClass of 1991

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2007 - 2025
CA State Medical License 1993 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Mixed Chimeric Transplantation for Primary Amyloidosis Start of enrollment: 2000 Dec 01
Withdrawn
Not Applicable
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) Start of enrollment: 2021 May 05
Completed
Phase 2
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Start of enrollment: 2022 Apr 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.
Cheng, R., Kittleson, M., Wechalekar, A., Alvarez-Cardona, J., Mitchell, J., Scarlatelli Macedo, A., Dutra, J., Campbell, C., Liu, J., Landau, H., Davis, M., Morrissey...> ;Heart. 2024 Jan 24
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 M...
Michael Slade, Mark A Fiala, Marie Kirchmeyer, Jeff King, Feng Gao, Mark A Schroeder, A Keith Stewart, Keith Stockerl-Goldstein, Christine Chen, Ravi Vij> ;Transplantation and Cellular Therapy. 2023 Dec 1
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Ziheng Xu, Jaebok Choi, Matthew Cooper, Jeffrey King, Mark A Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda Cashen, Meagan A Jacoby, Keith Stockerl-Goldstein, C...> ;Transplantation and Cellular Therapy. 2023 Nov 1
1 citations
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark A Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Kristen M S...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
1 citations
A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function.
Vahid Azimi, Michael Slade, Mark Fiala, Julie M Fortier, Keith Stockerl-Goldstein, John L Frater, Jonathan R Brestoff, Ronald Jackups, Mark A Zaydman> ;Clinical Chemistry. 2023 May 6
4 citations
The Dynamics of Financial Toxicity in Multiple Myeloma.
Mark A Fiala, Alice E Silberstein, Mark A Schroeder, Keith E Stockerl-Goldstein, Ravi Vij> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Apr 1
13 citations
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.
Zachary D Crees, Michael P Rettig, Reyka G Jayasinghe, Keith Stockerl-Goldstein, Sarah M Larson, Illes Arpad, Giulio A Milone, Massimo Martino, Patrick Stiff, Douglas ...> ;Nature Medicine. 2023 Apr 1
2 citations
Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study.
Michael Slade, Mark Fiala, Sarah Kelley, Zachary D Crees, Mark A Schroeder, Keith Stockerl-Goldstein, Ravi Vij> ;Leukemia Research. 2023 Apr 1
17 citations
Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Lawrence Wayne Liu, Alicia Yn, Feng Gao, Marissa Olson, Mallory Crain, Ramzi Abboud, Peter Westervelt, Camille Abboud, Ravi Vij, Keith Stockerl-Goldstein, Iskra Pusic,...> ;Transplantation and Cellular Therapy. 2022 Aug 1
4 citations
COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.
Zachary D Crees, Keith Stockerl-Goldstein> ;The American Journal of Medicine. 2022 Apr 1
What Do the Elevated Protein Levels Mean in My Patients with Myeloma, Amyloidosis, and Related Disorders?
Scott R Goldsmith, Keith Stockerl-Goldstein> ;The American Journal of Medicine. 2022 Apr 1
42 citations
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
Melissa M Berrien-Elliott, Jennifer A Foltz, David A Russler-Germain, Carly C Neal, Jennifer Tran, Margery Gang, Pamela Wong, Bryan Fisk, Celia C Cubitt, Nancy D Marin...> ;Science Translational Medicine. 2022 Feb 23
2 citations
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.
Meletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl-Goldstein, Paul G Richardson> ;Therapeutic Advances in Hematology. 2022 Jan 1
70 citations
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, M...> ;Journal of the National Comprehensive Cancer Network. 2022 Jan 1
7 citations
COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.
José Carlos Martínez, R Alejandro Sica, Keith Stockerl-Goldstein, Samuel M Rubinstein> ;Acta Haematologica. 2022 Jan 1
35 citations
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Amanda F. Cashen, Miriam T. Jacobs, Pamela Wong, Mark P. Foster, Ethan McClain, Sweta Desai, Patrick Pence, Sarah Co...> ;Blood. 2021 Nov 19
3 citations
How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis
Samuel M. Rubinstein, Keith Stockerl-Goldstein> ;JACC. Cardiooncology. 2021 Oct 1
8 citations
Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
Jingyu Xiang, Min Shi, Mark A. Fiala, Feng Gao, Michael P. Rettig, Geoffrey L. Uy, Mark A. Schroeder, Katherine N. Weilbaecher, Keith Stockerl-Goldstein, S. Mollah, Jo...> ;Blood Advances. 2021 Sep 23
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Dhakal, B., Patel, S., Girnius, S., Bachegowda, L., Fraser, R., Davila, O., Kanate, A., Assal, A., Hanbali, A., Bashey, A., Pawarode, A., Freytes, C., Lee, C., Vesole,...> ;Leukemia. 2021 Jul 1
1 citations
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma.
Lawrence Liu, Mark Fiala, Feng Gao, Justin King, Scott R. Goldsmith, Tanya M. Wildes, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder> ;Leukemia & Lymphoma. 2021 Jun 18
208 citations
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Petros Grivas, Ali Raza Khaki, Trisha Wise-Draper, Benjamin French, C. Hennessy, Chih-Yuan Hsu, Yu Shyr, X. Li, Toni K. Choueiri, Corrie A. Painter, Solange Peters, Br...> ;Annals of Oncology. 2021 Jun 1
2 citations
Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78.
Mark A. Fiala, Justin King, Daniel Feinberg, Scott R. Goldsmith, Mark A. Schroeder, Armin Ghobadi, Keith Stockerl-Goldstein, Ravi Vij, Tanya M. Wildes> ;Bone Marrow Transplantation. 2021 Apr 19
4 citations
A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.
Kathleen W. Zhang, Ray Zhang, Elena Deych, Keith Stockerl-Goldstein, John Gorcsan, Daniel J. Lenihan> ;American Heart Journal. 2021 Feb 1
3 citations
A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes
Eric Huselton, Michael P. Rettig, Theresa Fletcher, Julie Ritchey, Leah Gehrs, Kyle McFarland, Stephanie Christ, William C. Eades, Kathryn Trinkaus, Rizwan Romee, Shas...> ;Leukemia & Lymphoma. 2021 Jan 19
6 citations
Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.
Erica K. Barnell, Kenneth F. Newcomer, Zachary L. Skidmore, Kilannin Krysiak, Sydney R. Anderson, Lukas D. Wartman, Stephen T. Oh, John S. Welch, Keith Stockerl-Goldst...> ;JCO Precision Oncology. 2021 Jan 14
Join now to see all

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...
Keith E. Stockerl-Goldstein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell TransplantationMay 26th, 2021
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer Patients, Study FindsDecember 11th, 2010